2023
Combinatorial Immunotherapy with Agonistic CD40 Activates Dendritic Cells to Express IL12 and Overcomes PD-1 Resistance.
Krykbaeva I, Bridges K, Damsky W, Pizzurro G, Alexander A, McGeary M, Park K, Muthusamy V, Eyles J, Luheshi N, Turner N, Weiss S, Olino K, Kaech S, Kluger H, Miller-Jensen K, Bosenberg M. Combinatorial Immunotherapy with Agonistic CD40 Activates Dendritic Cells to Express IL12 and Overcomes PD-1 Resistance. Cancer Immunology Research 2023, 11: 1332-1350. PMID: 37478171, DOI: 10.1158/2326-6066.cir-22-0699.Peer-Reviewed Original ResearchConceptsPD-1 resistanceDendritic cellsTumor regressionAnti-PD-1 resistanceActivates Dendritic CellsCytokine secretion profilingSystemic cytokine profileTriple therapy combinationInnate immune activationAdaptive immune responsesComplete tumor regressionMajority of miceSignificant clinical challengeMouse melanoma modelT cell activationAgonistic CD40Checkpoint inhibitorsDC subsetsTriple therapyCytokine profileImmune activationCombinatorial immunotherapyTherapy combinationsT cellsClinical challenge
2019
Pathology of B cell and neutrophil infiltration in the YUMMER1.7 mouse model of spontaneous melanoma tumor regression
Blenman K, Wang J, Cowper S, Bosenberg M. Pathology of B cell and neutrophil infiltration in the YUMMER1.7 mouse model of spontaneous melanoma tumor regression. The Journal Of Immunology 2019, 202: 136.25-136.25. DOI: 10.4049/jimmunol.202.supp.136.25.Peer-Reviewed Original ResearchB cellsMelanoma cellsTumor regressionPlasmablasts/plasma cellsTumor-infiltrating B cellsLonger progression-free survivalMelanoma tumor regressionProgression-free survivalAdaptive immune responsesB cell numbersNeutrophil extracellular trapsNeutrophil infiltrationImmunotherapy treatmentSpontaneous regressionMetastatic melanomaAdverse reactionsGeographic necrosisImmune cellsNeutrophil responseHistological changesExtracellular trapsPlasma cellsImmune responseTherapy showTumor mass